eXoZymes Statistics
Total Valuation
eXoZymes has a market cap or net worth of $168.75 million. The enterprise value is $174.38 million.
Important Dates
The next estimated earnings date is Tuesday, March 4, 2025, before market open.
| Earnings Date | Mar 4, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
eXoZymes has 9.53 million shares outstanding. The number of shares has increased by 0.09% in one year.
| Current Share Class | 9.53M |
| Shares Outstanding | 9.53M |
| Shares Change (YoY) | +0.09% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 23.88% |
| Owned by Institutions (%) | 41.78% |
| Float | 7.25M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -241,078.56 |
| Forward PS | n/a |
| PB Ratio | -46.86 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.25
| Current Ratio | 0.25 |
| Quick Ratio | 0.14 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -66.29 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -88.29% |
| Return on Invested Capital (ROIC) | -145.10% |
| Return on Capital Employed (ROCE) | 220.07% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$176,687 |
| Employee Count | 29 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, eXoZymes has paid $44,410 in taxes.
| Income Tax | 44,410 |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 15.66 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 56.10 |
| Average Volume (20 Days) | 22,949 |
Short Selling Information
The latest short interest is 24,326, so 0.26% of the outstanding shares have been sold short.
| Short Interest | 24,326 |
| Short Previous Month | 23,197 |
| Short % of Shares Out | 0.26% |
| Short % of Float | 0.34% |
| Short Ratio (days to cover) | 0.60 |
Income Statement
In the last 12 months, eXoZymes had revenue of -$700 and -$5.12 million in losses. Loss per share was -$0.82.
| Revenue | -700 |
| Gross Profit | -700 |
| Operating Income | -4.93M |
| Pretax Income | n/a |
| Net Income | -5.12M |
| EBITDA | -4.68M |
| EBIT | -4.93M |
| Loss Per Share | -$0.82 |
Full Income StatementBalance Sheet
The company has $233,935 in cash and $5.86 million in debt, giving a net cash position of -$5.63 million or -$0.59 per share.
| Cash & Cash Equivalents | 233,935 |
| Total Debt | 5.86M |
| Net Cash | -5.63M |
| Net Cash Per Share | -$0.59 |
| Equity (Book Value) | -3.60M |
| Book Value Per Share | -0.58 |
| Working Capital | -4.38M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$3.58 million and capital expenditures -$295,788, giving a free cash flow of -$3.88 million.
| Operating Cash Flow | -3.58M |
| Capital Expenditures | -295,788 |
| Free Cash Flow | -3.88M |
| FCF Per Share | -$0.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | 704,833.71% |
| Pretax Margin | 725,645.00% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |